­

About mkulwiec

This author has not yet filled in any details.
So far mkulwiec has created 17 blog entries.

Tarsa Therapeutics Advances Its Oral Calcitonin for the Treatment and Prevention of Postmenopausal Osteoporosis

Completes Patient Enrollment in Phase II Osteoporosis Prevention Trial
Will Present Full Data Set on Phase III ORACAL Treatment Trial at ASBMR
Closes Additional Tranche of a Financing That Has Raised a Total of $24.5 Million
PHILADELPHIA, PA – July 12, 2011 —Tarsa Therapeutics today reported progress in its two ongoing  clinical development programs for its oral recombinant salmon […]

Tarsa Therapeutics Reports Positive Top-Line Results from Pivotal Phase III Oracal Trial of Its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis

Positive, Statistically Significant Top-Line Results Support Proceeding to NDA Submission in 2011
Trial Conducted in Accordance with Special Protocol Assessment with FDA
Full Results to Be Presented in Peer-Reviewed Forum Later this Year
PHILADELPHIA, PA – March 24, 2011 —Tarsa Therapeutics today announced that the Phase III ORACAL trial of its oral recombinant salmon calcitonin in the treatment of […]

Tarsa Therapeutics Completes Phase III Trial of Its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention

Completes Patient Dosing in ORACAL Trial; Results Expected in Early Spring
Enrollment Opened in New Phase II Postmenopausal Osteoporosis Prevention Trial
PHILADELPHIA, PA – February 14, 2011 — Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company’s once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis.  Results from the ORACAL […]

Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment Of Osteoarthritis

Philadelphia, PA, Boonton, NJ and Brussels, Belgium – September 24, 2010—Tarsa Therapeutics, Inc. and Unigene Laboratories, Inc. (OTCBB: UGNE) today reported preclinical data showing that calcitonin may have synergistic effects in combination with other drugs in reducing the collagen degradation associated with osteoarthritis.  The data are being presented at the 2010 Osteoarthritis Research Society International […]

Tarsa Therapeutics Advances Phase III Oracal Trial of Its Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis

—Completes Patient Enrollment in Global, Randomized, Double-Blind Phase III Trial—
—Receives Positive Safety Reports from Two Separate Reviews by Independent Data Monitoring Committee—
PHILADELPHIA, PA – July 22, 2010 — Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis.  The company has completed patient enrollment in […]

Unigene Licenses Phase III Oral Calcitonin Program to Tarsa Therapeutics

New Company Established by Unigene and Three Leading Venture Capital Firms Launched with $24 Million Series A Financing
BOONTON, NJ and PHILADELPHIA, PA – October 20, 2009 — Unigene Laboratories, Inc. (OTCBB: UGNE) and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by […]

Unigene to Host Conference Call to Discuss Phase III Oral Calcitonin Licensing Agreement with Tarsa Therapeutics

Conference Call Wednesday, October 21st, 9:00 AM EDT

BOONTON, N.J.–(BUSINESS WIRE)–Oct. 20, 2009– Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) will host a conference call on Wednesday, October 21, 2009, at 9:00 AM EDT to update investors on the Company’s recently announced agreement to license Unigene’s Phase III oral calcitonin program to Tarsa Therapeutics.

Unigene invites all those […]